Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Translational Development Acquisition (TDAC) Other Accumulated Expenses (2024 - 2026)

Translational Development Acquisition's Other Accumulated Expenses history spans 3 years, with the latest figure at $136762.0 for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses rose 509.92% to $136762.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $136762.0, a 509.92% increase, with the full-year FY2025 number at $106762.0, up 5238.1% from a year prior.
  • Other Accumulated Expenses came in at $136762.0 for Q1 2026, up from $106762.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $136762.0 in Q1 2026, with the low at $2000.0 in Q4 2024.
  • Historically, Other Accumulated Expenses has averaged $65245.2 across 3 years, with a median of $61762.0 in 2025.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 5238.1% in 2025 and later surged 509.92% in 2026.
  • Year by year, Other Accumulated Expenses stood at $2000.0 in 2024, then soared by 5238.1% to $106762.0 in 2025, then grew by 28.1% to $136762.0 in 2026.
  • Business Quant data shows Other Accumulated Expenses for TDAC at $136762.0 in Q1 2026, $106762.0 in Q4 2025, and $76762.0 in Q3 2025.